Last reviewed · How we verify
Sotalol or Amiodarone
Sotalol and Amiodarone are antiarrhythmic drugs that block potassium channels and slow electrical conduction in the heart to restore and maintain normal heart rhythm.
Sotalol and Amiodarone are antiarrhythmic drugs that block potassium channels and slow electrical conduction in the heart to restore and maintain normal heart rhythm. Used for Atrial fibrillation for rhythm control and stroke prevention, Ventricular arrhythmias including ventricular tachycardia, Supraventricular tachycardia.
At a glance
| Generic name | Sotalol or Amiodarone |
|---|---|
| Sponsor | Universitaire Ziekenhuizen KU Leuven |
| Drug class | Class III antiarrhythmic (Sotalol); Class I/II/III/IV antiarrhythmic (Amiodarone) |
| Target | Potassium channels (hERG); Beta-adrenergic receptors (Sotalol); Sodium channels, potassium channels, beta-adrenergic receptors, calcium channels (Amiodarone) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Sotalol is a Class III antiarrhythmic with beta-blocking properties that prolongs the action potential duration and refractory period. Amiodarone is a Class I, II, III, and IV antiarrhythmic with multiple mechanisms including sodium channel blockade, beta-blockade, potassium channel blockade, and calcium channel antagonism, making it effective against a broad spectrum of arrhythmias.
Approved indications
- Atrial fibrillation for rhythm control and stroke prevention
- Ventricular arrhythmias including ventricular tachycardia
- Supraventricular tachycardia
- Maintenance of sinus rhythm after cardioversion
Common side effects
- Bradycardia
- Hypotension
- Fatigue
- Dizziness
- QT prolongation
- Torsades de pointes
- Pulmonary toxicity (Amiodarone)
- Thyroid dysfunction (Amiodarone)
- Hepatotoxicity
Key clinical trials
- Non-Invasive Programmed Stimulation (NIPS) to Guide the Subsequent VT Therapeutic Strategies (NA)
- The PIVATAL Study -Study of Ventricular Arrhythmia (VTA) Ablation in Left Ventricular Assist Device (LVAD) Patients (PHASE4)
- Catheter Ablation Versus Anti-arrhythmic Drugs for Ventricular Tachycardia (NA)
- Efficacy of Early Rhythm Control Therapy in Patients With Subclinical Atrial Fibrillation (NA)
- Flecainide Safety in Patients With Coronary Artery Disease and Atrial Fibrillation (PHASE4)
- EfFect of Ablation of Persistent AtriaL Fibrillation on COgNitive Function in Individuals With Mild Cognitive Impairment (NA)
- Assessing the Neurological Outcomes After Atrial Fibrillation Ablation for Rhythm Control
- Prospective Multicenter Randomized and Controlled Study Evaluating the Benefit of Early Pulmonary Vein Isolation Compared to Usual Treatment in Patients Aged Over 75 Years and Presenting With Atrial Fibrillation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sotalol or Amiodarone CI brief — competitive landscape report
- Sotalol or Amiodarone updates RSS · CI watch RSS
- Universitaire Ziekenhuizen KU Leuven portfolio CI